169 related articles for article (PubMed ID: 33199389)
1. Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum.
McCarthy JS; Abd-Rahman AN; Collins KA; Marquart L; Griffin P; Kümmel A; Fuchs A; Winnips C; Mishra V; Csermak-Renner K; Jain JP; Gandhi P
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199389
[TBL] [Abstract][Full Text] [Related]
2. Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria.
Hien TT; White NJ; Thuy-Nhien NT; Hoa NT; Thuan PD; Tarning J; Nosten F; Magnusson B; Jain JP; Hamed K
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872070
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
[TBL] [Abstract][Full Text] [Related]
4. Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa.
Ndayisaba G; Yeka A; Asante KP; Grobusch MP; Karita E; Mugerwa H; Asiimwe S; Oduro A; Fofana B; Doumbia S; Jain JP; Barsainya S; Kullak-Ublick GA; Su G; Schmitt EK; Csermak K; Gandhi P; Hughes D
Malar J; 2021 Dec; 20(1):478. PubMed ID: 34930267
[TBL] [Abstract][Full Text] [Related]
5. DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with
Collins KA; Rückle T; Elliott S; Marquart L; Ballard E; Chalon S; Griffin P; Möhrle JJ; McCarthy JS
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30858218
[TBL] [Abstract][Full Text] [Related]
6. Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria.
Wattanakul T; Baker M; Mohrle J; McWhinney B; Hoglund RM; McCarthy JS; Tarning J
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468477
[TBL] [Abstract][Full Text] [Related]
7. Characterising the blood-stage antimalarial activity of pyronaridine in healthy volunteers experimentally infected with Plasmodium falciparum.
Barber BE; Webster R; Potter AJ; Llewellyn S; Sahai N; Leelasena I; Mathison S; Kuritz K; Flynn J; Chalon S; Marrast AC; Gobeau N; Moehrle JJ
Int J Antimicrob Agents; 2024 Jul; 64(1):107196. PubMed ID: 38734217
[TBL] [Abstract][Full Text] [Related]
8. Spiroindolone KAE609 for falciparum and vivax malaria.
White NJ; Pukrittayakamee S; Phyo AP; Rueangweerayut R; Nosten F; Jittamala P; Jeeyapant A; Jain JP; Lefèvre G; Li R; Magnusson B; Diagana TT; Leong FJ
N Engl J Med; 2014 Jul; 371(5):403-10. PubMed ID: 25075833
[TBL] [Abstract][Full Text] [Related]
9. A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers.
McCarthy JS; Rückle T; Elliott SL; Ballard E; Collins KA; Marquart L; Griffin P; Chalon S; Möhrle JJ
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685476
[TBL] [Abstract][Full Text] [Related]
10. Assessment
Yipsirimetee A; Chiewpoo P; Tripura R; Lek D; Day NPJ; Dondorp AM; Pukrittayakamee S; White NJ; Chotivanich K
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0148121. PubMed ID: 34978886
[TBL] [Abstract][Full Text] [Related]
11. Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection.
Collins KA; Abd-Rahman AN; Marquart L; Ballard E; Gobeau N; Griffin P; Chalon S; Möhrle JJ; McCarthy JS
J Infect Dis; 2022 Mar; 225(6):1062-1069. PubMed ID: 32479608
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.
McCarthy JS; Yalkinoglu Ö; Odedra A; Webster R; Oeuvray C; Tappert A; Bezuidenhout D; Giddins MJ; Dhingra SK; Fidock DA; Marquart L; Webb L; Yin X; Khandelwal A; Bagchus WM
Lancet Infect Dis; 2021 Dec; 21(12):1713-1724. PubMed ID: 34715032
[TBL] [Abstract][Full Text] [Related]
13. A G358S mutation in the Plasmodium falciparum Na
Qiu D; Pei JV; Rosling JEO; Thathy V; Li D; Xue Y; Tanner JD; Penington JS; Aw YTV; Aw JYH; Xu G; Tripathi AK; Gnadig NF; Yeo T; Fairhurst KJ; Stokes BH; Murithi JM; Kümpornsin K; Hasemer H; Dennis ASM; Ridgway MC; Schmitt EK; Straimer J; Papenfuss AT; Lee MCS; Corry B; Sinnis P; Fidock DA; van Dooren GG; Kirk K; Lehane AM
Nat Commun; 2022 Sep; 13(1):5746. PubMed ID: 36180431
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum.
Barber BE; Abd-Rahman AN; Webster R; Potter AJ; Llewellyn S; Marquart L; Sahai N; Leelasena I; Birrell GW; Edstein MD; Shanks GD; Wesche D; Moehrle JJ; McCarthy JS
Clin Infect Dis; 2023 Jun; 76(11):1919-1927. PubMed ID: 36795050
[TBL] [Abstract][Full Text] [Related]
15. The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound.
Bouwman SA; Zoleko-Manego R; Renner KC; Schmitt EK; Mombo-Ngoma G; Grobusch MP
Travel Med Infect Dis; 2020; 36():101765. PubMed ID: 32561392
[TBL] [Abstract][Full Text] [Related]
16. Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.
Barber BE; Fernandez M; Patel HB; Barcelo C; Woolley SD; Patel H; Llewellyn S; Abd-Rahman AN; Sharma S; Jain M; Ghoghari A; Di Resta I; Fuchs A; Deni I; Yeo T; Mok S; Fidock DA; Chalon S; Möhrle JJ; Parmar D; McCarthy JS; Kansagra K
Lancet Infect Dis; 2022 Jun; 22(6):879-890. PubMed ID: 35247321
[TBL] [Abstract][Full Text] [Related]
17. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.
McCarthy JS; Rückle T; Djeriou E; Cantalloube C; Ter-Minassian D; Baker M; O'Rourke P; Griffin P; Marquart L; Hooft van Huijsduijnen R; Möhrle JJ
Malar J; 2016 Sep; 15(1):469. PubMed ID: 27624471
[TBL] [Abstract][Full Text] [Related]
18. Biochemical characterization and chemical inhibition of PfATP4-associated Na
Rosling JEO; Ridgway MC; Summers RL; Kirk K; Lehane AM
J Biol Chem; 2018 Aug; 293(34):13327-13337. PubMed ID: 29986883
[TBL] [Abstract][Full Text] [Related]
19. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.
Phyo AP; Jittamala P; Nosten FH; Pukrittayakamee S; Imwong M; White NJ; Duparc S; Macintyre F; Baker M; Möhrle JJ
Lancet Infect Dis; 2016 Jan; 16(1):61-69. PubMed ID: 26448141
[TBL] [Abstract][Full Text] [Related]
20. Cation ATPase (ATP4) Orthologue Replacement in the Malaria Parasite Plasmodium knowlesi Reveals Species-Specific Responses to ATP4-Targeting Drugs.
Mohring F; van Schalkwyk DA; Henrici RC; Blasco B; Leroy D; Sutherland CJ; Moon RW
mBio; 2022 Oct; 13(5):e0117822. PubMed ID: 36190127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
